News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gloucester Pharmaceuticals, Inc. Release: ISTODAX(R) Incorporated Into National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology(TM) for the Treatment of Cutaneous T-cell Lymphoma (CTCL)


12/3/2009 12:32:09 PM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gloucester Pharmaceuticals announced today that ISTODAX® (romidepsin) has been included in the updated National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology™ as a suggested systemic treatment option for patients with mycosis fungoides and Sézary syndrome—two of the most common types of cutaneous T-cell lymphoma (CTCL). ISTODAX, a member of a new class of cancer drugs known as histone deacetylase (HDAC) inhibitors, received FDA approval in early November for the treatment of CTCL in patients who have received at least one prior systemic therapy.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES